

# Mild To Moderate Plaque Psoriasis - Pipeline Insight, 2021

<https://marketpublishers.com/r/MEFD99CCD66DEN.html>

Date: February 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: MEFD99CCD66DEN

## Abstracts

This report can be delivered to the clients within 48-72 Hours

DelveInsight's, "Mild To Moderate Plaque Psoriasis - Pipeline Insight, 2021," report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Mild To Moderate Plaque Psoriasis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

## Geography Covered

Global coverage

## Mild To Moderate Plaque Psoriasis Understanding

### Mild To Moderate Plaque Psoriasis: Overview

Psoriasis is a genetically determined, systemic, immune-mediated long-term inflammatory condition that affects the skin, nails and joints. When psoriasis affects more than 5 percent of your body, it's considered moderate to severe. It may affect your genitals, face, hands, and feet. Biologic drugs are a popular treatment option for this type of psoriasis. Biologics may be used alone or with other treatments to ease your psoriasis. The doctor may assess the severity by looking at the physical symptoms of psoriasis. They may look for erythema (redness), scaling, and induration (lesion thickness). These three signs are often used to classify the severity of psoriasis.

“Mild To Moderate Plaque Psoriasis - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Mild To Moderate Plaque Psoriasis pipeline landscape is provided which includes the disease overview and Mild To Moderate Plaque Psoriasis treatment guidelines. The assessment part of the report embraces, in depth Mild To Moderate Plaque Psoriasis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Mild To Moderate Plaque Psoriasis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

## **Report Highlights**

The companies and academics are working to assess challenges and seek opportunities that could influence Mild To Moderate Plaque Psoriasis R&D. The therapies under development are focused on novel approaches to treat/improve Mild To Moderate Plaque Psoriasis.

### **Mild To Moderate Plaque Psoriasis Emerging Drugs Chapters**

This segment of the Mild To Moderate Plaque Psoriasis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

### **Mild To Moderate Plaque Psoriasis Emerging Drugs**

#### **Roflumilast topical: Arcutis Biotherapeutics**

Topical roflumilast cream (ARQ-151) is a small molecule inhibitor of phosphodiesterase type 4 (PDE4), an intracellular enzyme that increases the production of proinflammatory mediators and decreases production of anti-inflammatory mediators, and has been implicated in a wide range of inflammatory diseases including psoriasis. The drug is currently in phase 3 of clinical trials for the treatment of mild to moderate psoriasis.

#### **CC-90006: AnaptysBio**

AnaptysBio-generated anti-inflammatory antibody programs, and has initiated a Phase 1 trial for CC-90006, a PD-1 agonist antibody, which is indicated for psoriasis.

Further product details are provided in the report.....

### Mild To Moderate Plaque Psoriasis: Therapeutic Assessment

This segment of the report provides insights about the different Mild To Moderate Plaque Psoriasis drugs segregated based on following parameters that define the scope of the report, such as:

### Major Players in Mild To Moderate Plaque Psoriasis

There are approx. 4+ key companies which are developing the therapies for Mild To Moderate Plaque Psoriasis. The companies which have their Mild To Moderate Plaque Psoriasis drug candidates in the most advanced stage, i.e. phase III include, Acrutis Biotherapeutics Biopharma.

### Phases

DelveInsight's report covers around 4+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

### Route of Administration

Mild To Moderate Plaque Psoriasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized

under various ROAs such as

Oral

Parenteral

intravitreal

Subretinal

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

## **Product Type**

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

### **Mild To Moderate Plaque Psoriasis: Pipeline Development Activities**

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Mild To Moderate Plaque Psoriasis therapeutic drugs key players involved in developing key drugs.

## **Pipeline Development Activities**

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Mild To Moderate Plaque Psoriasis drugs.

### **Mild To Moderate Plaque Psoriasis Report Insights**

Mild To Moderate Plaque Psoriasis Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

### **Mild To Moderate Plaque Psoriasis Report Assessment**

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

## **Key Questions**

### **Current Treatment Scenario and Emerging Therapies:**

How many companies are developing Mild To Moderate Plaque Psoriasis drugs?

How many Mild To Moderate Plaque Psoriasis drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Mild To Moderate Plaque Psoriasis?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Mild To Moderate Plaque Psoriasis therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Mild To Moderate Plaque Psoriasis and their status?

What are the key designations that have been granted to the emerging drugs?

## **Key Players**

Acrutis Biotherapeutics

AnaptysBio

Evelo Biosciences

## **Key Products**

Roflumilast topical

CC-90006

EDP1815

## Contents

Introduction

Executive Summary

Mild To Moderate Plaque Psoriasis: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Mild To Moderate Plaque Psoriasis – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Mild To Moderate Plaque Psoriasis companies' collaborations, Licensing, Acquisition  
-Deal Value Trends

Mild To Moderate Plaque Psoriasis Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Roflumilast topical: Acrutis Biotherapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

CC-90006: AnaptysBio

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Mild To Moderate Plaque Psoriasis Key Companies

Mild To Moderate Plaque Psoriasis Key Products

Mild To Moderate Plaque Psoriasis- Unmet Needs

Mild To Moderate Plaque Psoriasis- Market Drivers and Barriers

Mild To Moderate Plaque Psoriasis- Future Perspectives and Conclusion

Mild To Moderate Plaque Psoriasis Analyst Views

Mild To Moderate Plaque Psoriasis Key Companies

Appendix



## List Of Tables

### LIST OF TABLES

Table 1 Total Products for Mild To Moderate Plaque Psoriasis

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

Figure 1 Total Products for Mild To Moderate Plaque Psoriasis

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

## I would like to order

Product name: Mild To Moderate Plaque Psoriasis - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/MEFD99CCD66DEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MEFD99CCD66DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970